Skip to content

Annexon ANNX Prepaid & Other Current

Prepaid & Other Current at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$620.9M+32.4%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$7.42M+9.6%
Omeros logo
OmerosOMER
$7.35M-1.6%
Vor Biopharma logo
Vor BiopharmaVOR
$6.39M+41.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$9.52M-31.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$20.44M+81.2%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's prepaid & other current?
Annexon (ANNX) reported prepaid & other current of $3.24M in Q1 2026.
How has Annexon's prepaid & other current changed year-over-year?
Annexon's prepaid & other current decreased by 27.4% year-over-year, from $4.47M to $3.24M.
What is the long-term trend for Annexon's prepaid & other current?
Over 4 years (2021 to 2025), Annexon's prepaid & other current has grown at a 1.7% compound annual growth rate (CAGR), from $14.98M to $16.02M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.